Project ALS and Amylyx Enter Collaboration to Test AMX0035

  1. Home
  2. news
  3. Project ALS and Amylyx Enter Collaboration to Test AMX0035

Project ALS and Amylyx Enter Collaboration to Test AMX0035  

Amylyx closes a $ 5 million Series A Investment
Previous
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Next

Recent Posts

  • Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
  • Search for cure against the lethal disease ALS boosted by new investor
  • Orphazyme closes a €14 million Series B Extension
  • Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
  • Project ALS and Amylyx Enter Collaboration to Test AMX0035

ROBERT BROWN

Scientific Advisory Board